1-(3-chlorophenyl)-5,5-dimethylpiperazin-2-one | 1000047-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-chlorophenyl)-5,5-dimethylpiperazin-2-one
• CAS: 1000047-49-3
• 化学式: C₁₂H₁₅ClN₂O
• 分子量: 238.717
• InChiKey: UAAREKPYBVFQOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-chlorophenyl)-5,5-dimethylpiperazin-2-one 、 (3S,5S)-3-isopropyl-5-[(2S)-1-(2-nitrobenzenesulfonyl)aziridine-2-yl]dihydrofuran-2-one 以 甲苯 为溶剂， 生成 N-((S)-2-(4-(3-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl)-1-((2S,4S)-4-isopropyl-5-oxotetrahydrofuran-2-yl)ethyl)-2-nitrobenzenesulfonamide
  参考文献：
  名称：

  Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors

  摘要：

  Introduction of the 2,2-dimethyl-4-phenylpiperazin-5-one scaffold into the P-3-P-1 portion of the (2S,4S,5S)-5-amino-6-dialkylamino-4-hydroxy-2-isopropylhexanamide backbone dramatically increased the renin inhibitory activity without using the interaction to the S-3(sp) pocket. Compound 31 exhibited >10,000-fold selectivity over other human proteases, and 18.5% oral bioavailability in monkey. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.092
• 作为产物：
  描述：

  tert-butyl 4-(3-chlorophenyl)-2,2-dimethyl-5-oxopiperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(3-chlorophenyl)-5,5-dimethylpiperazin-2-one
  参考文献：
  名称：

  Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors

  摘要：

  Introduction of the 2,2-dimethyl-4-phenylpiperazin-5-one scaffold into the P-3-P-1 portion of the (2S,4S,5S)-5-amino-6-dialkylamino-4-hydroxy-2-isopropylhexanamide backbone dramatically increased the renin inhibitory activity without using the interaction to the S-3(sp) pocket. Compound 31 exhibited >10,000-fold selectivity over other human proteases, and 18.5% oral bioavailability in monkey. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.092

文献信息

• CYCLIC AMINE COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2036896B1

  公开（公告）日：2012-03-14
• US8158790B2
  申请人：——

  公开号：US8158790B2

  公开（公告）日：2012-04-17
• Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors
  作者：Yuji Nakamura、Chie Sugita、Masaki Meguro、Shojiro Miyazaki、Kazuhiko Tamaki、Mizuki Takahashi、Yoko Nagai、Takahiro Nagayama、Mikio Kato、Hiroshi Suemune、Takahide Nishi

  DOI：10.1016/j.bmcl.2012.05.092

  日期：2012.7

  Introduction of the 2,2-dimethyl-4-phenylpiperazin-5-one scaffold into the P-3-P-1 portion of the (2S,4S,5S)-5-amino-6-dialkylamino-4-hydroxy-2-isopropylhexanamide backbone dramatically increased the renin inhibitory activity without using the interaction to the S-3(sp) pocket. Compound 31 exhibited >10,000-fold selectivity over other human proteases, and 18.5% oral bioavailability in monkey. (C) 2012 Elsevier Ltd. All rights reserved.